Dr. Wisniewski has been a consultant for Bristol-Myers Squibb, Case Western University, Cyberonics, ImaRx Therapeutics, and Organon over the last 4 years. In the last 5 years, Dr. Rush has received research support from NIMH and the Stanley Medical Research Institute; during that time he has been an advisory board member, consultant, and/or speaker for Advanced Neuromodulation Systems, AstraZeneca, Best Practice Project Management, Bristol-Myers Squibb, Cyberonics, Forest, Gerson Lehman Group, GlaxoSmithKline, Jazz, Magellan Health Services, Merck, Neuronetics, Novartis, Ono, Organon, Otsuka, Pam Labs, Pfizer, Trancept, The Urban Institute, and Wyeth; he has equity holdings (excluding mutual funds and blinded trusts) in Pfizer; he receives royalties from Guilford Publications and Healthcare Technology Systems; and he receives a stipend as treasurer of the Society of Biological Psychiatry. Dr. Nierenberg has received research support in the past 3 years from Cederroth, Cyberonics, Forest, Medtronics, NIMH, NARSAD, Ortho-McNeil-Janssen, Pam Labs, Pfizer, Shire, and the Stanley Foundation through the Broad Institute; past research support includes Bristol-Myers Squibb, Cederroth, Eli Lilly, Forest, GlaxoSmithKline, Janssen, Lichtwer, Pfizer, and Wyeth; he has received honoraria from the Massachusetts General Hospital (MGH) Psychiatry Academy (2008 academy activities were supported through Independent Medical Education grants from AstraZeneca, Eli Lilly, and Janssen) and has participated in no other speakers bureaus for the past 3 years; past speakers bureaus have included Bristol-Myers Squibb, Cyberonics, Eli Lilly, Forest, GlaxoSmithKline, and Wyeth; he has provided advisory or consulting services in the past 3 years to Abbott, Appliance Computing, Brain Cells, Bristol-Myers Squibb, Eli Lilly, EpiQ, Forest, GlaxoSmithKline, Janssen, Jazz, Merck, Novartis, Pam Labs, Pfizer, PGx Health, Schering-Plough, Sepracor, Shire, Somerset, Takeda, and Targacept; he has received royalties from Cambridge University Press and Belvoir Publishing; he owns stock options in Appliance Computing; he holds copyrights to the Clinical Positive Affect Scale and the MGH Structured Clinical Interview for the Montgomery Asberg Depression Scale exclusively licensed to the MGH Clinical Trials Network and Institute (CTNI). Dr. Gaynes has received grants and research support in the last 12 months from the Agency for Healthcare Research and Quality, Bristol-Myers Squibb, M-3 Information, NIMH, and Novartis; he has served as an advisor for Bristol-Myers Squibb. Dr. Warden currently owns stock in Pfizer and has owned stock in Bristol-Myers Squibb within the last 5 years. Dr. McGrath has received research support in the last 5 years from Eli Lilly, GlaxoSmithKline, Lipha, NARSAD, the National Institute on Alcohol Abuse and Alcoholism, the New York State Department of Mental Hygiene, NIMH, Organon, and the Research Foundation for Mental Hygiene (New York State); he has been on advisory boards or consulted for GlaxoSmithKline, Novartis, Roche, Sanofi-Aventis, and Somerset. Dr. Lavori has received funding in the past 5 years from NIH and the Department of Veterans Affairs; he has received consulting fees from ARCA Discoveries, BMS, Celera Diagnostics, Corcept, Cyberonics, Fibrogen, Forest, Leif Cabrezer, Neuronetics, the Palo Alto Medical Foundation Research Institute, and Pfizer. Dr. Thase has received research funding from Eli Lilly and Sepracor; he has served in an advisory or consulting capacity to, or received speakers honoraria from, AstraZeneca, Bristol-Myers Squibb, Cephalon, Cyberonics, Eli Lilly, Forest, GlaxoSmithKline, Janssen, MedAvante, Neuronetics, Novartis, Organon, Sanofi-Aventis, Schering-Plough, Sepracor, Shire, Supernus, and Wyeth; he has equity holdings in MedAvante; he has provided expert testimony for Jones Day (Wyeth litigation), Phillips Lytle (GlaxoSmithKline litigation), and Pepper Hamilton (Eli Lilly litigation); he has received royalty, patent, or other income from American Psychiatric Publishing, Guilford Publications, Herald House, and W.W. Norton; his spouse is Senior Medical Director for Advogent (formerly Cardinal Health). Dr. Fava has received research support from Abbott, Alkermes, Aspect Medical Systems, AstraZeneca, Bristol-Myers Squibb, Cephalon, Eli Lilly, Forest, GlaxoSmithKline, J&J Pharmaceuticals, Lichtwer, Lorex, Novartis, Organon, Pam Labs, Pfizer, Pharmavite, Roche, Sanofi-Aventis, Solvay, Synthelabo, and Wyeth; he has provided advisory or consulting services to Abbott, Amarin, Aspect Medical Systems, AstraZeneca, Auspex, Bayer, Best Practice Project Management, Biovail, BrainCells, Bristol-Myers Squibb, Cephalon, CNS Response, Compellis, Cypress, Dov, Eli Lilly, EPIX, Fabre-Kramer, Forest, GlaxoSmithKline, Grunenthal, Janssen, Jazz, J&J Pharmaceuticals, Knoll, Lorex, Lundbeck, MedAvante, Merck, Neuronetics, Novartis, Nutrition 21, Organon, Pam Labs, Pfizer, PharmaStar, Pharmavite, Precision Human Biolaboratory, Roche, Sanofi-Aventis, Sepracor, Solvay, Somaxon, Somerset, Synthelabo, Takeda, Tetragenex, Transcept, Vanda, and Wyeth; he has served on the speakers bureaus of AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Cephalon, Eli Lilly, Forest, GlaxoSmithKline, Novartis, Organon, Pfizer, PharmaStar, Primedia, Reed-Elsevier, and Wyeth; he has equity holdings with Compellis; he has applied for patents for SPCD and for a combination of azapirones and bupropion in major depressive disorder; and he receives royalties for the MGH CPFQ, DESS, and SAFER. Dr. Trivedi has received research support from the Agency for Healthcare Research and Quality, Corcept, Cyberonics, Merck, the National Alliance for Research in Schizophrenia and Depression, the National Institute on Drug Abuse, NIMH, Novartis, Pharmacia & Upjohn, Predix, Solvay, and Targacept; and he has received consulting or speaking fees from Abbott, Abdi Brahim, Akzo (Organon), AstraZeneca, Bristol-Myers Squibb, Cephalon, Eli Lilly, Fabre-Kramer, Forest, GlaxoSmithKline, Janssen, Johnson & Johnson, Meade Johnson, Neuronetics, Parke-Davis, Pfizer, Sepracor, VantagePoint, and Wyeth. Mr. Luther reports no competing interests.